CVS Caremark Zepbound coverage is coming back. Starting October 1, 2026, CVS Caremark will add Zepbound (tirzepatide) back to its standard commercial formularies as a preferred option, sitting alongside Wegovy instead of being replaced by it. If you were forced to switch to Wegovy in mid-2025, or you have been paying cash for Zepbound ever since, this is the change you have been waiting for. Here is what is actually changing, who it applies to, and the practical steps to take before and after October 1.
What is changing with CVS Caremark Zepbound coverage?
A quick recap. In May 2025, CVS Caremark announced it was dropping Zepbound from its most common commercial formularies effective July 1, 2025, and making Wegovy (semaglutide) the preferred GLP-1 for weight management. Roughly 25 to 30 million members were affected, and many people on Zepbound had to switch to Wegovy, appeal, or pay out of pocket.
On May 28, 2026, CVS Health announced a reversal. The key points:
- Zepbound returns October 1, 2026 as an additional preferred option on CVS Caremark’s template commercial formularies.
- Wegovy stays preferred too, both the injection and the Wegovy pill. If you are stable on Wegovy, nothing forces you to move.
- Foundayo (orforglipron), Lilly’s daily GLP-1 pill, had its new-to-market block removed on June 1, 2026, where plans approve coverage.
- Same tier, no penalty. For participating plans, Zepbound and Wegovy will sit at the same formulary tier, so choosing one over the other should not cost you a higher copay.
The reason, according to CVS, is a new pricing agreement with Eli Lilly. After a year of negotiations, the cost came down enough for Caremark to put both brands back on the list.
Does the new CVS Caremark Zepbound coverage apply to you?
This is the part most headlines skip. CVS Caremark is a pharmacy benefit manager, not your insurance plan. It builds template formularies, but your employer or health plan chooses whether to adopt them and can customize coverage. So the October 1 change applies if:
- Your prescription benefits are managed by CVS Caremark (check your pharmacy card or the Caremark app).
- Your plan uses one of Caremark’s standard commercial formularies, such as Advanced Control or Standard Control.
- Your plan covers weight-management GLP-1s at all. Many employers exclude the whole category, and this announcement does not change that. If your plan is cutting the benefit for next year, see what to do when your employer drops GLP-1 coverage in 2027.
Medicare plans work differently. If you are on Medicare Part D, the relevant program is the Medicare GLP-1 Bridge, which offers a $50 monthly copay for eligible beneficiaries from July 1, 2026 through December 31, 2027.
The easiest way to confirm: log in to Caremark.com or the app, use the “Check Drug Cost” tool for Zepbound, and look at the coverage status for dates on or after October 1. If it still shows as not covered, call the member services number on your card and ask whether your plan sponsor adopted the updated formulary.
Prior authorization: what to expect
Coverage returning does not mean automatic approval. Nearly every plan that covers Zepbound requires prior authorization (PA), a form your prescriber submits showing you meet the plan’s criteria. Typical requirements include:
- A BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, sleep apnea, or type 2 diabetes.
- Documentation of a lifestyle program (diet and exercise) alongside the medication.
- For renewals, proof of response, often a 5% weight loss within the first several months.
If you were on Zepbound before the 2025 change, ask your provider’s office whether your old PA records and weight history can be attached to the new request. Your logged weights from the past year are useful evidence here. If you have been keeping a weight and dose history, export it and bring it to the appointment. You can track all of it free with Pep, which stores your dose log, weight trend, and side-effect notes in one place so the paperwork takes minutes instead of an afternoon of digging through old texts and photos.
Switching back from Wegovy to Zepbound
If you moved to Wegovy in 2025 and want to return to Zepbound, here is what to know. First, there is no official one-to-one dose conversion between semaglutide and tirzepatide. They are different molecules with different dose ladders: Wegovy runs 0.25, 0.5, 1, 1.7, and 2.4 mg weekly (plus the newer 7.2 mg Wegovy HD), while Zepbound runs 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. Your prescriber will choose a Zepbound starting dose based on your history, your current tolerance, and how much appetite control you have. Some people go back to a dose near where they left off; others restart lower to limit nausea.
A few practical tips for the transition:
- Do not overlap doses. Both are once-weekly injections, and the usual approach is to take Zepbound when your next Wegovy dose would have been due. Confirm the timing with your prescriber or pharmacist.
- Expect a side-effect reset. Even at a familiar dose, switching molecules can bring back early-weeks nausea, fatigue, or constipation for a couple of weeks. Our guides on reducing nausea and constipation relief cover the basics.
- Map out the ladder. If you are restarting at a lower dose, the free GLP-1 dose schedule calculator shows when each step-up could land so you know what to expect month by month.
- Log the switch date. Note the last Wegovy dose and first Zepbound dose. If side effects or a plateau show up later, the timeline makes the cause obvious to you and your provider.
For a deeper comparison of the two medications, including trial results and typical weight loss, see Zepbound vs Wegovy.
What it will cost after October 1
Your exact copay depends on your plan’s tier structure, but here are the numbers to know:
- Lilly’s Zepbound savings card can bring the cost down to as little as $25 a month for eligible commercially insured patients whose plan covers Zepbound. The card does not work for Medicare or Medicaid.
- Self-pay Zepbound vials through LillyDirect currently run about $299 to $449 a month depending on dose, with the current pricing program scheduled through December 31, 2026. That is the fallback if your plan opts out.
- Wegovy self-pay is currently $349 a month for the injection and less for the pill, which matters if you are weighing whether switching back is worth it.
To compare scenarios side by side, plug your plan’s copay and the self-pay options into the GLP-1 cost calculator, and see our full breakdown of what GLP-1s cost in 2026.
A timeline for the next few weeks
- Now: Confirm your benefits are through CVS Caremark and check whether your plan covers weight-management GLP-1s. Ask HR or your plan if they are adopting the October formulary update.
- Mid-to-late September: Book an appointment or send a portal message to your prescriber. Ask them to prepare the Zepbound prior authorization so it can be submitted the moment coverage is active. Gather your weight and dose history.
- October 1 onward: Have the pharmacy run Zepbound. If it rejects, ask whether it is a PA issue (fixable) or a plan exclusion (talk to HR). Register for the Lilly savings card before your first fill.
- First 4 weeks on Zepbound: Log each dose, your weekly weight, and any side effects so you and your provider can judge the transition with real data instead of memory.
The 2025 formulary change caused a surge of medication switching: Truveta data presented in 2026 showed monthly switching away from tirzepatide jumped roughly 17-fold in the months after the change. Expect a similar wave in the other direction this fall, which means pharmacy and PA backlogs. Getting the paperwork in early is the best way to avoid a gap in treatment.
CVS Caremark Zepbound coverage FAQ
When does CVS Caremark Zepbound coverage start?
October 1, 2026, for commercial plans that use CVS Caremark’s standard template formularies and cover weight-management GLP-1s. Individual plan sponsors can customize coverage, so confirm with your plan.
Do I have to switch from Wegovy back to Zepbound?
No. Wegovy injection and the Wegovy pill remain preferred on CVS Caremark formularies, and members currently on Wegovy can continue without interruption. Switching is a choice you and your prescriber make, not a requirement.
Will CVS Caremark Zepbound coverage require prior authorization?
Almost certainly. Most plans require a PA confirming BMI criteria and a lifestyle program, and renewals often require documented weight loss. Ask your prescriber to prepare the request before October 1 so it is ready to submit.
Download Pep free — track your shots, pills & progress in one app.
This article is for educational purposes only and is not medical or insurance advice. Coverage details vary by plan; confirm with CVS Caremark, your plan sponsor, and your healthcare provider.